- Home
- SAND vs HCM Comparison
SAND vs HCM Comparison
Compare SAND & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- HCM
- Stock Information
- Founded
- SAND 2007
- HCM 2000
- Country
- SAND Canada
- HCM Hong Kong
- Employees
- SAND N/A
- HCM N/A
- Industry
- SAND
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- SAND
- HCM Health Care
- Exchange
- SAND NYSE
- HCM Nasdaq
- Market Cap
- SAND 2.4B
- HCM 2.5B
- IPO Year
- SAND N/A
- HCM N/A
- Fundamental
- Price
- SAND $8.83
- HCM $13.89
- Analyst Decision
- SAND Buy
- HCM Hold
- Analyst Count
- SAND 4
- HCM 1
- Target Price
- SAND $9.13
- HCM $19.00
- AVG Volume (30 Days)
- SAND 4.6M
- HCM 62.8K
- Earning Date
- SAND 05-06-2025
- HCM 03-19-2025
- Dividend Yield
- SAND 0.64%
- HCM N/A
- EPS Growth
- SAND 32.83
- HCM N/A
- EPS
- SAND 0.10
- HCM 0.04
- Revenue
- SAND $183,537,000.00
- HCM $630,201,000.00
- Revenue This Year
- SAND $17.55
- HCM $14.86
- Revenue Next Year
- SAND $10.62
- HCM $19.54
- P/E Ratio
- SAND $89.02
- HCM $63.20
- Revenue Growth
- SAND 2.84
- HCM N/A
- 52 Week Low
- SAND $4.92
- HCM $11.51
- 52 Week High
- SAND $9.03
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- SAND 60.03
- HCM 50.07
- Support Level
- SAND $7.93
- HCM $13.13
- Resistance Level
- SAND $9.03
- HCM $13.66
- Average True Range (ATR)
- SAND 0.21
- HCM 0.36
- MACD
- SAND 0.02
- HCM 0.05
- Stochastic Oscillator
- SAND 82.91
- HCM 81.25
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.